Abstracts tagged "Cohort Study"

Abstract Number: 2083 • ACR Convergence 2024
A Novel Scoring System to Predict a Cancer Development in Patients with Idiopathic Inflammatory Myopathy
Yun Kyu Kim¹, Ju yeon Kim², Jung Yoon Pyo³, Min Jung Kim⁴, Jin Kyun Park⁵, Eun Young Lee⁶, Yun Jong lee³, eun Bong Lee¹ and Jun Won park², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University Hospital, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ³Seoul National University Bundang Hospital, Seongnam-si, ⁴Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ⁵Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, ⁶3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Previous studies have demonstrated that idiopathic inflammatory myopathy (IIM) is associated with an elevated cancer risk. However, there is limited evidence on the specific…
Abstract Number: 2330 • ACR Convergence 2024
Mental Health, Sex, and Comorbidities as Determinants of Recalcitrant PsA
Rebecca haberman¹, Seungha Um², Catherine Howe³, Kyra Chen², Brianna Fu², Adamary Felipe², Stephanie Eichman², Margaret Coyle⁴, Eileen Lydon⁵, Andrea Neimann², Soumya Reddy⁶, Samrachana Adhikari² and Jose Scher⁷, ¹NYU Langone Health, New York, NY, ²NYU Grossman School of Medicine, NYC, ³New York University Langone Medical Center, New York, NY, ⁴NYU Langone, Brooklyn, NY, ⁵NYU, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷New York University School of Medicine, New York, NY
Background/Purpose: Despite significant advances in therapeutics over the past two decades, psoriatic arthritis (PsA) remains difficult to treat, with joint outcomes lagging far behind those…
Abstract Number: 0268 • ACR Convergence 2024
Weight Loss Induced by Anti-obesity Medications and Gout Among Overweight and Obesity Individuals: A Population-based Cohort Study
Jie Wei¹, Yilun Wang², Nicola Dalbeth³, Junqing Xie⁴, Jing Wu⁵, Chao Zeng⁶, Guanghua Lei⁷ and Yuqing Zhang⁸, ¹Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ²Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ³University of Auckland, Auckland, New Zealand, ⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁵Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, China (People's Republic), ⁶Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ⁷Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ⁸Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Weight loss is conditionally recommended for gout management; however, the magnitude of the effect of weight loss on incident gout and recurrent gout flares…
Abstract Number: 0581 • ACR Convergence 2024
Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with reduced radiographic progression and improved quality of life among patients (pts) with PsA.1 Clinical advances made MDA…
Abstract Number: 1023 • ACR Convergence 2024
Factors Associated with Delays in Dispensation and Insurance Denials of Janus Kinase Inhibitors
Igor Dombrovsky¹, Michael George², Joshua Baker² and Thomas Riley³, ¹Pennsylvania Hospital, Philadephia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Hopsital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Access to Janus kinase inhibitors (JAKi) is controlled by insurance carriers through prior authorizations and the use of restricted formularies. We previously showed that…
Abstract Number: 1335 • ACR Convergence 2024
The Association of Patient-Reported Non-Articular Pain with Musculoskeletal Pain Diagnoses and RA Disease Activity in a Prospective Real-World Cohort of Patients with Early RA
Charis Meng¹, Margaret Butler¹, Deanna Jannat-Khah¹, Yvonne Lee², Clifton Bingham³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University, Chicago, IL, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Non-articular pain (NAP) is often reported by early RA (eRA) patients, impacts RA remission (REM) but remains poorly defined and this hampers RA care.…
Abstract Number: 1574 • ACR Convergence 2024
Therapeutic Strategy in Patients with Mixed Connective Tissue Disease: A Multicenter Retrospective Study in the French MCTD Cohort
Kevin Chevalier¹, Benjamin Thoreau², Marc Michel³, Bertrand Godeau⁴, Christian AGARD⁵, Thomas Papo⁶, Karim Sacré⁶, Raphaele Seror⁷, Xavier Mariette⁸, Patrice Cacoub⁹, Ygal Benhamou¹⁰, Hervé Levesque¹⁰, Cécile Goujard¹¹, Olivier Lambotte¹¹, Bernard Bonnotte¹², Maxime SAMSON¹³, Felix Ackermann¹⁴, Jean Schmidt¹⁵, Pierre Duhaut¹⁶, Jean-Emmanuel Kahn¹⁷, Thomas Hanslik¹⁷, Nathalie Costedoat-chalumeau¹⁸, Benjamin Terrier¹⁹, Alexis Régent²⁰, bertrand Dunogue², Pascal cohen²¹, Veronique LE GUERN²², Eric Hachulla²³, Luc Mouthon² and Benjamin Chaigne²⁴, ¹Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France, Paris, France, ²Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ³2. Department of Internal Medicine, Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil (UPEC), Créteil, France., Créteil, France, ⁴Department of Internal Medicine, Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil (UPEC), Créteil, France., Créteil, France, ⁵Nantes University Hospital, Nantes, France, ⁶Université Paris Cité, Paris, France, ⁷Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ⁹Sorbonne Université, Paris, ¹⁰Department of Internal Medicine, CHU de Rouen, UniRouen, Rouen, France., Rouen, France, ¹¹Université Paris Saclay, Department of Internal Medicine and clinical immunology, Bicêtre hospital, Assistance Publique-Hôpitaux de Paris, UMR1184 Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin-Bicêtre, France, ¹²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France., Dijon, France, ¹³Dijon University Hospital, Dijon, France, ¹⁴Department of Internal Medicine, Foch Hospital, Suresnes, France., Suresnes, France, ¹⁵Department of Internal Medicine and RECIF, Amiens University Hospital, Université Picardie Jules Verne, Amiens, France., Amiens, France, ¹⁶Department of Internal Medicine and RECIF, Amiens-Picardie University Hospital, AMIENS, France, ¹⁷Department of Internal Medicine, Ambroise Paré Hospital, Assistance Publique - Hôpitaux de Paris, Université de Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France, Boulogne Billancourt, France, ¹⁸University Paris Cité, Paris, France, ¹⁹Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ²⁰National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ²¹National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ²²Cochin hospital, Paris, France, ²³Department of Internal Medicine and clinical immunology, North-West National Reference Center for Rare Systemic Autoimmune Diseases iques et Auto-Immunes Rares du Nord-Ouest, Hôpital Claude Huriez, Université de Lille, France, Lille, France, ²⁴Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Mixed connective tissue disease (MCTD) is a rare systemic disorder that belongs to connective tissue diseases (CTD). Few studies are available on MCTD treatment.…
Abstract Number: 2129 • ACR Convergence 2024
Fracture Risk Assessment Tool (FRAX®) Scores Predict Mortality in Community-Dwelling Elderlies
Thiago Quadrante Freitas¹, Leonardo Olalla², Luana Machado³, Camille Figueiredo³, Liliam Takayama⁴, Valeria Caparbo³, Ricardo Oliveira⁵, Diogo Domiciano¹ and Rosa M R Pereira³, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Quito, Ecuador, ³Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, SP, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵RDO DIAGNÓSTICOS MÉDICOS, São Paulo, SP, Brazil
Background/Purpose: The World Health Organization Fracture Risk Assessment Tool (FRAX®) was developed to estimate the 10-year absolute probability of osteoporotic fractures among the general population.…
Abstract Number: 2342 • ACR Convergence 2024
Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Lihi Eder¹, Carlo Selmi², Philip Mease³, Alexis Ogdie⁴, Francois Nantel⁵, Frederic Lavie⁶, Mohamed Sharaf⁷, Oyediran Adelakun⁸, Emmanouil Rampakakis⁹, Laura PINA VEGAS¹⁰ and Laura Coates¹¹, ¹University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ²IRCCS Istituto Clinico Humanitas, Rozzano, Italy, ³Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Nantel MedSci Consult, Montreal, QC, Canada, ⁶Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁷Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ⁸Janssen Research & Development, LLC, Titusville, NJ, ⁹McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom
Background/Purpose: PsA occurs in males and females at similar rates. Females participating in randomized controlled trials (RCTs) have shown lower treatment efficacy based on composite…
Abstract Number: 0280 • ACR Convergence 2024
Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform
Mark Russell¹, Jon Massey², Edward Roddy³, Brian MacKenna⁴, Seb Bacon⁴, Ben Goldacre⁴, Colm Andrews⁴, George Hickman⁴, Amir Mehrkar², Arti Mahto⁵, Andrew Rutherford⁶, Samir Patel¹, Maryam Adas⁷, Edward Alveyn⁷, deepak Nagra¹, Katie Bechman⁷, Joanna Ledingham⁸, Joanna Hudson⁹, Sam Norton¹, Andrew Cope⁷ and James Galloway¹⁰, ¹King's College London, London, England, United Kingdom, ²University of Oxford, Oxford, England, United Kingdom, ³Keele University, Keele, England, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵King's College Hospital NHS Foundation Trust, London, United Kingdom, ⁶King's College Hospital NHS Foundation Trust, London, England, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁹King's College London, King's College London, United Kingdom, ¹⁰Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Data from before the COVID-19 pandemic had shown persistently poor care for people with gout in many countries worldwide. Whether this was further exacerbated…
Abstract Number: 0582 • ACR Convergence 2024
Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with clinically meaningful improvements in disease activity and patient (pt)-reported outcomes among pts with PsA.1 However, it is…
Abstract Number: 1051 • ACR Convergence 2024
Healthcare Costs and Resource Utilization Associated with Long-term Medium-to-high Dose Oral Corticosteroid Use in Patients with Dermatomyositis or Polymyositis
Daniel Labson¹, Qian Cai², Concetta Crivera³ and Federico Zazzetti⁴, ¹Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Raritan, NJ, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Titusville, NJ, ³Janssen Global Services, LLC, a Johnson & Johnson Company, Immunology Market Access, Horsham, PA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare autoimmune conditions primarily characterized by muscle weakness and inflammation. Real-world evidence on economic outcomes of patients with…
Abstract Number: 1338 • ACR Convergence 2024
Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Mark Tatangelo³ and Claire Bombardier³, and OBRI investigators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) have approximately a twofold increased risk of developing herpes zoster (HZ) compared to the general population. This elevated risk is attributed…
Abstract Number: 1582 • ACR Convergence 2024
Impact of Immunosuppressive Treatment on Development and Survival in Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Stefano Rodolfi¹, Cheryl Chun Man Ng², Ana Maria Ruiz Bejerano², Medha Kanitkar², Voon Ong³ and Christopher Denton⁴, ¹Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²University College London, London, United Kingdom, ³University College London, London, England, United Kingdom, ⁴University College London, Northwood, United Kingdom
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe and frequently life-threatening complication of systemic sclerosis (SSc). Treatment of SSc-PAH follows the same approach of idiopathic…
Abstract Number: 2133 • ACR Convergence 2024
Unveiling the Association Between Low-Density Lipoprotein Cholesterol Lowering and Fracture Risk Among Patients with Hyperlipidaemia in a Population-Based Cohort Study: The Lower, the Better
Zeqin Wen¹, Yilun Wang¹, Xiaoxiao Li², Yuqing Zhang³, Junqing Xie⁴, Houchen Lyu⁵, Changjun Li², Jie Wei⁶, Guanghua Lei⁷ and Chao Zeng⁸, ¹Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ²Central South University, Changsha, China (People's Republic), ³Massachusetts General Hospital, Quincy, MA, ⁴University of Oxford, Oxford, United Kingdom, ⁵Central South University, Beijing, China, ⁶Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ⁷Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ⁸Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic)
Background/Purpose: High low-density lipoprotein cholesterol (LDL-C) is a major risk factor for fracture; however, whether LDL-C lowering induced by statins is associated with decreased fracture…

« Previous Page
1
…
4
5
6
7
8
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].